EMA OKs new measures to minimize jaw osteonecrosis with Aclasta
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has completed another review of the risk of osteonecrosis of the jaw with Novartis' bisphosphonate drug Aclasta (zoledronic acid) and has recommended that while the risk remains very low, a number of precautionary measures should be introduced, including updates to the product information and the launch of a patient reminder card.